Patent classifications
C07D215/227
Methods and Compositions for Targeting Tregs using CCR8 Inhibitors
The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
##STR00001##
NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS
The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.
NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS
The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.
SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1
The invention relates generally to novel EPAC1 activators, such as Formula I and II and the preparation thereof as well as the use of EPAC1 activators disclosed herein as to selectively activate EPAC1 in cells.
##STR00001##
##STR00002##
BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
ANTI-SARS-COV-2 DRUG
The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I):
##STR00001##
[wherein R.sup.1 is C.sub.1-C.sub.8 alkyl or the like; and R.sup.2-R.sup.9 is hydrogen, halogen, hydroxyl, or Q-(C.sub.1-C.sub.8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.
COMPOUNDS ACTIVE TOWARDS BROMODOMAINS
Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
##STR00001##
COMPOUNDS ACTIVE TOWARDS BROMODOMAINS
Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
##STR00001##